W Kim, JJ Poterucha, JE Hermans, TM … - Annals of internal medicine, 1997 - Am Coll Physicians Background: Interferon-α is effective in only a small number of patients with
chronic hepatitis C, although prolonged treatment may increase the response
rate. There is concern that the expense of interferon-α therapy may not be ... Cited by 125 - Related articles - BL Direct - All 5 versions
WG Bennett, Y Inoue, JR Beck, JB Wong, SG … - Annals of internal medicine, 1997 - Am Coll Physicians For author affiliations and current author addresses, see end of text. From the
University of Florida College of Medicine, Gainesville, Florida; Baylor College
of Medicine, Houston, Texas; Yamaguchi University School of Medicine, Ube, ... Cited by 220 - Related articles - BL Direct - All 6 versions
ZM Younossi, ME Singer, JG McHutchison, … - Hepatology, 1999 - interscience.wiley.com Treatment of chronic hepatitis C with Interferon (IFN) 2b monotherapy results in
10% to 15% sustained virological response (SVR). Combining IFN with ribavirin
increases this response. In this analysis, using the Markov model, 6 ... Cited by 125 - Related articles - BL Direct - All 4 versions
JB Wong, WG Bennett, RS Koff, SG Pauker - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context.— Chronic ... Cited by 148 - Related articles - BL Direct - All 6 versions
JB Wong, T Poynard, MH Ling, JK Albrecht, … - Am J Gastroenterol, 2000 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 72 - Related articles - BL Direct - All 7 versions
JB Wong, GL Davis, SG Pauker - The American journal of medicine, 2000 - Elsevier Chronic hepatitis C affects 170 million persons worldwide and nearly 3 million
in the United States [1 and 2], resulting in >8,000 deaths annually and
accounting for >20% of all liver transplants in the United States [3]. ... Cited by 38 - Related articles - BL Direct - All 8 versions
- ►googlepages.com [PDF] JA Salomon, MC Weinstein, JK Hammitt, SJ … - Jama, 2003 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context Approximately 2.7 ... Cited by 120 - Related articles - BL Direct - All 16 versions
ME Singer, ZM Younossi - The American journal of medicine, 2001 - Elsevier We used a Markov decision analysis model to estimate the lifetime cost
effectiveness of three screening strategies: (1) initial screening for hepatitis
C antibody by third-generation enzyme-linked immunosorbent assay (ELISA), ... Cited by 33 - Related articles - BL Direct - All 13 versions
GM Dusheiko, JA Roberts - Hepatology, 1995 - interscience.wiley.com The aim of this study is to assess the long-term economic impact of treatment of
chronic hepatitis B and C with interferon alfa. Estimates were made of the
progression of the disease over a 30-year period using a transitional ... Cited by 119 - Related articles - BL Direct - All 3 versions
GL Davis, JR Beck, G Farrell, T Poynard - Journal of Viral Hepatitis, 1998 - interscience.wiley.com Short courses (6 months) of interferon (IFN) are highly cost-effective in
patients with histologically mild chronic hepatitis C. However, IFN treatment
lasting 12–24 months is now the standard of care. We utilized a ... Cited by 16 - Related articles - BL Direct - All 3 versions
